What Novo-Passit Treats: Main Uses and Benefits

Novo-Passit is commonly used to help manage symptoms associated with mild forms of neurasthenic syndrome and general nervous exhaustion. This includes addressing persistent fatigue, decreased concentration, and general weakness linked to chronic stress. It may provide supportive relief by easing the overall symptom burden, which is relevant across various contexts. The key herbal components are applicable for the temporary relief of symptoms associated with stress such as mild anxiety and irritability, including symptoms associated with menopause.

The medication is commonly used for managing emotional manifestations of stress, such as heightened irritability, internal restlessness, and nervous fear or sadness, while also addressing physical discomforts like stress-related physical tension and vasomotor headaches. It is also relevant for functional issues such as mild insomnia caused by nervous tension and the supportive management of nervous symptoms during the climacteric period. The use of this preparation helps patients cope more steadily with symptom fluctuations arising from everyday nervous strain and temporary high-pressure situations.

“This preparation supports the patient during difficult episodes by easing distress and promoting a sense of emotional balance.”

---

Quick Fact: Used for Supportive Relief of Nervous Tension and Related Physical Discomforts

Regulatory References

1. MHRA Herbal Registration overview

Official Population Eligibility Rules for Novo-Passit

Regulatory documentation defines strict parameters for who is permitted and who is prohibited from using Novo-Passit.

Eligibility Scope	Regulatory Status
Populations Allowed	Adults and adolescents aged 12 years and older.
Geriatric Use	Use in patients over 65 years is generally permitted without mandatory dose adjustment.

Absolute Contraindications	Prohibited Populations
Disease-Related	Patients with Myasthenia Gravis or Epilepsy.
Organ Function	Patients with Severe Hepatic Insufficiency (Severe Liver Failure).
Sensitivity	Individuals with known Hypersensitivity to Guaifenesin or any component.
Physiological State	Pregnancy and the period of Lactation/Breastfeeding.
Pediatric	Children under 12 years of age are not recommended for use.

Eligibility-Related Restrictions also prohibit the use of Novo-Passit in patients concurrently taking medications such as Cyclosporine, Tacrolimus, or Protease Inhibitors, as the co-administration is classified as contraindicated by regulatory instructions.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Novo-Passit, which is classified as a sedative combination due to its inclusion of Guaifenesin and sedative herbal extracts, such as Valerian.

---

Pharmacodynamic Reinforcement

The primary interaction risk is a pharmacodynamic reinforcement with substances that depress the Central Nervous System (CNS), potentially resulting in additive or synergistic sedation, increased drowsiness, and psychomotor impairment. Medicinal product categories involved include:

• CNS Depressants: Such as Benzodiazepines, Barbiturates, and Opioid Analgesics.
• Anesthetics: Co-administration with general anesthetics is restricted due to the risk of compounded sedative effects.

Substance and Timing Restrictions

Co-ingestion with Alcohol (Ethanol) is documented to potentiate the sedative effects of the active components, contributing to enhanced CNS depression. An interaction-related procedural constraint requires the product to be discontinued at least two weeks before any scheduled surgical procedure due to the potential for interaction with anesthetic agents.

Metabolic Pathway Interference

The herbal components may also be associated with pharmacokinetic pathway interference, specifically involving the metabolism of co-administered medicinal products. This potential is documented for substrates of the Cytochrome P450 3A4 (CYP3A4) enzyme and medications cleared via Glucuronidation, which may alter the systemic exposure of these drugs.

Novo-Passit's function stems from the combined action of its herbal components and the synthetic anxiolytic, guaifenesin. The herbal extract blend modulates neuronal excitability within the central nervous system (CNS). Compounds such as valerenic acid and various flavonoids present in the formulation interact with GABA-A receptors, primarily targeting allosteric sites. This interaction leads to an increase in the frequency of chloride ion channel opening, which hyperpolarizes the neuronal membrane. This cellular process dampens the rate of action potential firing, consequently reducing the overall release of excitatory neurotransmitters in the CNS.

Concurrently, guaifenesin acts upon nerve fibers by reducing the sensitivity of afferent neural pathways. Mechanistically, it is thought to inhibit synaptic transmission, which decreases the responsiveness of the reticular formation to incoming peripheral and central stimuli. This dual-pronged effect—one via GABAergic modulation and the other through general depressant activity—culminates in a measurable reduction in overall peripheral and central nervous system reactivity to stressors.

Administration Guidelines: Official Use of Novo-Passit

The use of Novo-Passit is strictly defined by the oral administration route and the availability of its two authorized dosage formats: the oral solution and film-coated tablets. The procedural instructions govern the standardized intake of the preparation, ensuring consistency with regulatory guidelines.

---

Administration Scope

Field	Official Instruction Principle
Route of administration	Oral (by mouth)
Dosing schedule	Usage adheres to a standardized course of treatment for symptomatic purposes.
Preparation requirements	The oral solution may be taken either undiluted or after mixing with a small volume of non-alcoholic liquid.
Special procedural conditions	The film-coated tablets must be swallowed whole to preserve their structural integrity during administration.

---

Official Use Protocol

The preparation is intended to be used within a divided daily schedule, though the specific numerical frequency and dosage must adhere precisely to the official prescribing information for the region in which the product is supplied. The oral route dictates that procedural steps focus on ingestion, where the film-coated tablets require whole swallowing, and the liquid allows for flexibility in mixing. The official instructions establish a controlled course of treatment focused on symptom management, with the specific duration and adjustment rules defined by the authoritative regulatory documents governing the medicine.

Research Evidence / Overview of Studies for Novo-Passit

Evidence for Mild Nervous Tension and Stress Symptoms

The evidence base for Novo-Passit, a preparation that combines seven plant extracts with the compound Guaifenesin, primarily draws upon research exploring its individual components and Traditional Use records. Researchers utilized short-term, controlled clinical trials (RCTs) to examine the component extracts in studies applied in research contexts involving fluctuating or unstable symptoms. Research explored how symptoms change over time, and studies monitored outcomes related to systemic or functional imbalance and physiological strain. The populations studied were typically adults experiencing conditions marked by functional limitations and stress.

Studies conducted during periods of increased symptom activity reported measurements of changes in subjective feelings of nervousness and restlessness. Findings describe patterns observed in the studies, with findings that were mixed across different clinical trials. Research describes that outcomes related to physical discomfort, such as tension and headaches, were studied in association with the synthetic component (Guaifenesin).

A key uncertainty is the lack of widely available, large-scale, published Randomized Controlled Trials (RCTs) focusing specifically on the fixed-dose, multi-component Novo-Passit formulation. Certainty remains low regarding the full combination’s research profile.

---

Research Structure for Mild Insomnia Due to Nervous Tension

Research examined the component herbs for mild insomnia, particularly for sleep disturbances that may be linked to nervous tension or restlessness. Studies were designed to assess outcomes reflecting daily functioning, specifically monitoring patient-reported outcomes describing perceived discomfort related to sleep. This included measurements of subjective sleep quality and sleep onset latency in adult populations presenting with mild insomnia complaints.

Data for the specific seven-herb and Guaifenesin combination remain insufficient to characterize the range of measured sleep outcomes. Long-term effects are not fully established, and research exploring sustained changes in sleep patterns is limited. The study results reflect the specific conditions under which they were conducted and research does not determine whether an individual will respond similarly over extended periods.

---

Evidence for Symptoms Associated with the Climacteric Period (Menopause)

The evidence structure for nervous symptoms associated with the climacteric period (menopause) draws primarily upon Traditional Herbal Registration (THR) data. This regulatory approach draws upon long-standing, historical use records of the component herbs for conditions involving periods of heightened symptoms of anxiety or restlessness.

However, the evidence is limited because this historical usage data is not supported by dedicated, large-scale Randomized Controlled Trials (RCTs) for the specific Novo-Passit combination in this group. Certainty remains low for subgroup findings.

Key Studies & References MHRA: Traditional Herbal Registrations (THRs) granted with indication and quantitative composition

Common questions about Novo-Passit (FAQ)

---

Q: Is Novo-Passit considered a strong sedative or is it milder?

A: Official product information classifies Novo-Passit as a sedative/anxiolytic combination. Regulatory documents specify that it can commonly cause effects such as drowsiness and dizziness. Warnings emphasize that these effects may be enhanced by co-administration with other substances that affect the Central Nervous System (CNS), such as alcohol.

Q: Can Novo-Passit be taken alongside supplements like melatonin or magnesium?

A: Regulatory documents caution against combining this drug with any substance that is known to cause Central Nervous System (CNS) depression. This is because combining these products can lead to additive sedative effects and potentially increased drowsiness. While specific supplements are not named, official warnings generally apply to use with other products known to cause drowsiness.

Q: Are there known interactions with common anti-depressant or anti-anxiety medications?

A: Official labeling restricts co-administration with medicines categorized as CNS depressants, which include certain anti-anxiety drugs like Benzodiazepines. The restriction is imposed due to the risk of compounded sedation and increased impairment. Information regarding use with medications affecting the central nervous system is available in the official prescribing information.

Q: Are there known interactions with birth control pills and Novo-Passit?

A: Official product information describes a potential for pharmacokinetic pathway interference caused by the herbal components. Specifically, this medicine may interact with drugs metabolized by the CYP3A4 enzyme or cleared via Glucuronidation. Since some oral contraceptives use these pathways, this potential metabolic alteration may affect their systemic exposure.

Q: Does Novo-Passit interact with pain relief medicines like NSAIDs?

A: Official regulatory documents do not list over-the-counter pain relievers, such as NSAIDs (non-steroidal anti-inflammatory drugs), as a category with a documented interaction. The primary documented risk is a pharmacodynamic reinforcement with substances that depress the Central Nervous System (CNS).

Q: What is the difference between Novo-Passit and valerian root extract?

A: Novo-Passit is a fixed-dose combination product containing seven different plant extracts, including Valerian, plus the synthetic component Guaifenesin. Valerian root extract is a single herbal ingredient. The inclusion of both components is intended to address both nervous tension and physical tension associated with stress, based on the product’s composition.

Q: Does Novo-Passit have a known 'hangover' feeling the next morning?

A: The official safety profile reports drowsiness as a common adverse effect. Regulatory texts caution that these Central Nervous System (CNS) effects may be more pronounced at the initiation of treatment or during any dose adjustment. The feeling described may be related to these reported sedative effects.

Q: Can Novo-Passit cause skin reactions or allergies?

A: The official safety profile lists Allergic reactions (Hypersensitivity) under Immune System Disorders as a rare adverse reaction. These reactions can sometimes manifest as skin-related issues. Concerns about allergic reactions are typically addressed by seeking immediate medical attention.

Q: Does the use of Novo-Passit require any special monitoring or testing?

A: Routine monitoring or testing is generally not specified in regulatory texts for this medicine. However, official precautions are advised for individuals who have existing severe hepatic (liver) or severe renal (kidney) impairment, which may necessitate medical oversight during use.

Q: Is Novo-Passit's use supported by a high level of clinical evidence?

A: Official documents note that the evidence primarily relies on research into the individual components and historical Traditional Use records. Certainty remains low regarding the full combination’s research profile due to a lack of widely available, large-scale Randomized Controlled Trials (RCTs) focusing specifically on the fixed-dose formulation.

Q: What does official guidance say about using Novo-Passit for exam-related stress?

A: The official therapeutic indication is defined for the relief of mild nervous tension and general stress symptoms. While this may cover some aspects of exam-related stress, the specific scenario of 'exam stress' is not directly referenced in the official guidance.

Q: Does the package insert provide information on what to do in case of an accidental overdose?

A: Yes, official documentation includes a dedicated section on Overdose. This section typically advises seeking immediate medical attention and provides information on potential symptoms and management, which primarily relate to the effects of guaifenesin and Central Nervous System (CNS) depression.

Q: Why is the drug intended for 'neurasthenia' and what does that term mean?

A: The term 'neurasthenia' is used in some regulatory contexts but is an older classification. The current therapeutic indication is generally described for the relief of symptoms related to nervous tension and stress. These symptoms may be described as irritability, chronic fatigue, headaches, or bodily weakness.

Q: Can I take Novo-Passit if I only feel nervous sometimes?

A: The product is officially indicated for the relief of symptoms related to nervous tension and stress. The official guidance describes usage as adhering to a standardized course of treatment for symptomatic purposes. This suggests its use is typically defined by the presence of these symptoms.

Q: Can Novo-Passit be taken if I have known kidney problems?

A: Official information states that the product is contraindicated (prohibited) for patients with severe renal (kidney) impairment. The official regulatory text does not specifically address use in cases of mild or moderate kidney issues.

Q: Are there warnings about taking Novo-Passit with other products containing guaifenesin?

A: Yes, official regulatory documents caution against taking the medicine with other products that contain Guaifenesin. The warning is intended to avoid exceeding the maximum daily limit for this active ingredient, as defined in the regulatory guidance.

Q: Can I use Novo-Passit before a medical procedure or surgery?

A: Official procedural constraints require that the product be discontinued at least two weeks before any scheduled surgical procedure. This restriction is documented due to the potential for interaction between the product's components and general anesthetic agents.

---

How to Store and Dispose of Novo-Passit?

Novo-Passit must be stored according to regulatory requirements to maintain its stability and effectiveness.

---

Official Storage Conditions

• Temperature: Store at a temperature not exceeding 25 C (77 F).
• Environmental Protection: The medicine must be protected from light.
• Container Rules: Store the product in its original container.
• Handling Restriction: The medicine must not be frozen.
• Child Safety: Keep the product out of the sight and reach of children.

---

Disposal Requirements

Any unused or expired medicine must be disposed of in accordance with local requirements for pharmaceutical waste. Do not dispose of the product via household waste or wastewater unless specifically authorized by local regulations.